gefitinib has been researched along with uric acid in 1 studies
| Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (uric acid) | Trials (uric acid) | Recent Studies (post-2010) (uric acid) |
|---|---|---|---|---|---|
| 5,231 | 566 | 2,919 | 27,980 | 1,717 | 9,982 |
| Protein | Taxonomy | gefitinib (IC50) | uric acid (IC50) |
|---|---|---|---|
| Solute carrier family 2, facilitated glucose transporter member 9 | Homo sapiens (human) | 300 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bao, W; Cheng, SB; Chin, YE; Liu, N; Qiu, A; Shi, Y; Wang, L; Xiong, C; Xu, L; Yan, H; Yang, T; Zhuang, S | 1 |
1 other study(ies) available for gefitinib and uric acid
| Article | Year |
|---|---|
EGF Receptor Inhibition Alleviates Hyperuricemic Nephropathy.
Topics: Animals; Chemokines; Cytokines; Disease Progression; ErbB Receptors; Fibroblasts; Fibrosis; Gefitinib; Hyperuricemia; Inflammation; Kidney; Kidney Diseases; Male; Phosphorylation; Quinazolines; Rats; Rats, Sprague-Dawley; Risk Factors; Signal Transduction; Transforming Growth Factor beta; Transforming Growth Factor beta1; Uric Acid | 2015 |